CION Ameerpet
Cervical Cancer Types · Reviewed by CION Oncologists · NABH Accredited
Adenosquamous & Mixed Cervical Cancers — When a Tumour Has Two Components
Occasionally a cervical cancer report describes not one cancer but two cell types in the same tumour — a glandular component and a squamous component growing together. That is adenosquamous carcinoma, and it is uncommon. Reading it can be unsettling, because it sounds as though you have been given two diagnoses at once. In practice you have one tumour that has differentiated in two directions, and the FIGO stage still sets the treatment pathway exactly as it does for the pure types. This page explains how pathologists confirm a genuinely mixed tumour, what the related terms mean, and which questions are actually worth asking your oncologist.
- One tumour, two components — not two separate cancers, and not a more complicated operation by definition
- Same FIGO 2018 staging — there is no separate staging system for mixed cervical cancers
- Confirmation matters — mucin stains and immunohistochemistry separate a true mixed tumour from its look-alikes
- Tumour board review — uncommon histology is exactly the situation a multidisciplinary meeting exists for
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
What “Adenosquamous” Actually Describes
The word is a compound of the two cell types the cervix is built from. Adeno refers to the mucus-producing glandular cells lining the cervical canal; squamous refers to the flat cells covering the outer surface. An adenosquamous carcinoma is a single tumour in which the pathologist can identify a malignant version of both, side by side in the same specimen.
How does one tumour end up looking two ways? The cervix has a border zone where glandular and squamous tissue meet, and the stem cells in that zone are capable of maturing down either route. When a cancer arises there, it can differentiate in both directions at once. This is why adenosquamous carcinoma is a cervical phenomenon rather than a coincidence — the anatomy makes it possible.
What it is not is two separate cancers requiring two separate treatments. Nor does the label by itself say anything about the stage. A woman with a small, node-negative adenosquamous tumour is in an entirely different position from one with bulky disease and involved nodes, however identical the histology line reads. If you want the background on how each component behaves on its own, our pages on squamous cell carcinoma of the cervix and cervical adenocarcinoma cover each in detail.
Did You Know? Glassy cell carcinoma — a term that alarms women who search for it — is not a separate disease in the current classification. The WHO classification of female genital tumours recognises it as a poorly differentiated form of adenosquamous carcinoma, named for the ground-glass appearance of its cytoplasm under the microscope. It is uncommon, and like other adenosquamous tumours it is staged and treated within the standard cervical cancer framework. Source: WHO Classification of Tumours, Female Genital Tumours, 5th edition (2020).
The Terms You May See on a Mixed-Tumour Report
Several of these look similar on paper and mean quite different things down the microscope. Knowing which is which tells you how much weight to put on the wording.
The diagnosis
Adenosquamous Carcinoma
Both a malignant glandular component and a malignant squamous component are present in the same tumour. Mucin stains are usually used to demonstrate that the glandular part is genuine rather than an artefact of how the tissue was cut.
A variant
Glassy Cell Carcinoma
A poorly differentiated adenosquamous carcinoma whose cells have a distinctive ground-glass cytoplasm. It is uncommon and has historically been regarded as behaving aggressively, which makes prompt, complete staging particularly important.
A look-alike
Squamous Carcinoma With Entrapped Glands
A squamous cancer growing around normal cervical glands can imitate a two-component tumour on a small biopsy. Because the glands themselves are benign, this is not adenosquamous carcinoma — and calling it so would be an over-diagnosis.
A look-alike
Adenocarcinoma With Squamous Metaplasia
A glandular cancer containing benign squamous change. Again, one malignant component only. Distinguishing this from a true adenosquamous tumour is a judgement call that additional stains and an experienced pathologist settle.
Important exception
Mixed Tumour With a Neuroendocrine Component
If any part of the tumour is neuroendocrine, that changes the plan — the neuroendocrine component drives management regardless of how small it is. See small cell and neuroendocrine cervical cancer.
How it is settled
Mucin Stains & Immunohistochemistry
Special stains show whether cells are truly producing mucin, and antibody-based staining identifies the lineage of each component. p16 and HPV testing are usually added, since most adenosquamous carcinomas of the cervix are HPV-associated.
A small punch biopsy samples a fraction of the tumour. It is common for a mixed component to be identified only on the larger surgical specimen — a change in wording that reflects better sampling, not a worsening disease.
What Is Worth Asking When Your Report Says “Mixed”
Uncommon histology invites a lot of anxious reading and not much clarity. These are the questions that genuinely change something:
- Has both components being malignant been confirmed? Ask whether mucin staining or immunohistochemistry was used, or whether the diagnosis rests on appearance alone on a small biopsy.
- Is there any neuroendocrine component? This is the single finding that would move you onto a different treatment pathway, and it should be actively excluded when a tumour is described as mixed.
- What is the FIGO stage? Stage, tumour size and node status remain the dominant factors in every decision that follows. The histology line does not override them.
- What do the MRI and PET-CT show? Complete staging matters more, not less, when the histology is unusual, because it removes the temptation to make decisions on the label alone.
- Has the case been to a tumour board? Uncommon pathology is precisely what multidisciplinary review exists for. Ask when the meeting is, and what was decided.
- Are the original slides available for review? Where a second opinion is being sought, the paraffin blocks and slides travel; the report alone is not enough for a pathologist to re-read.
On prognosis, honestly. Published series disagree about whether adenosquamous carcinoma behaves less favourably than the pure types. Some report poorer outcomes; others find no meaningful difference once stage, tumour size and lymph node status are accounted for. What is not in dispute is that stage at diagnosis and completing the planned treatment on schedule dominate the picture. That is where your attention is best spent.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Uncommon Histology Deserves a Second Reader
A mixed cervical tumour is exactly the case where an extra pathology opinion and a full staging work-up earn their place. Both are available across CION's 7 NABH-accredited Hyderabad locations.
Staging a Mixed Cervical Cancer
There is no adenosquamous staging system. The tumour is staged with FIGO 2018, the same framework used for every carcinoma of the cervix, and the work-up follows the same sequence.
Examination and tumour measurement
A clinical examination establishes whether the tumour has reached the vagina or the tissue beside the cervix. Since the 2018 revision, this finding is no longer the sole basis for the stage — imaging and pathology may be used as well — but it remains the starting point.
MRI of the pelvis
MRI measures the tumour, shows how far it has grown through the cervical wall, and defines the relationship to the parametrium, bladder and rectum. It is the study on which the local extent of the disease is judged.
PET-CT for lymph nodes and distant disease
Nodal status is part of the stage under FIGO 2018, so it must be assessed rather than assumed. PET-CT looks at pelvic and para-aortic nodes and excludes disease beyond the pelvis before a curative plan is committed to.
Pathology confirmation and exclusion of a neuroendocrine component
This is the step that is specific to mixed tumours. Both components are confirmed with stains, and any neuroendocrine element is looked for deliberately, because its presence would change the entire treatment approach.
Tumour board decision
Surgical, radiation and medical oncology review the histology, the imaging and your own circumstances together, and agree a plan before anything is offered — the approach NCCN and ESMO both recommend for cervical cancer of any histological type.
What Each Finding Does — and Does Not — Change
A quick way to judge how much weight a line on your report deserves. The right-hand column is the practical consequence, not a prognosis.
| Finding on the report | Does it change the treatment pathway? | What your team does with it |
|---|---|---|
| Adenosquamous carcinoma | No — the standard cervical pathway applies | Confirms both components; treatment set by stage, size and nodes |
| Glassy cell carcinoma | No separate pathway, but urgency increases | Complete staging quickly and avoid delay between steps |
| Any neuroendocrine component | Yes — this one genuinely does | Management is driven by the neuroendocrine part, however small |
| Squamous carcinoma with benign entrapped glands | No — it is not a mixed tumour at all | Reported and treated as squamous cell carcinoma |
| Lymphovascular space invasion present | Can influence treatment after surgery | Weighed alongside margins and node status at the tumour board |
| Positive lymph nodes | Yes — stage IIIC under FIGO 2018 | Shifts the plan towards chemoradiation with brachytherapy |
| Involved margins on a cone specimen | Yes | Further excision or additional treatment is usually recommended |
For the wider picture of how cervical cancer arises, is screened for and is prevented, start from the cervical cancer overview.
Did You Know? There is no separate treatment algorithm for adenosquamous cervical cancer. NCCN Guidelines for Cervical Cancer handle squamous cell carcinoma, adenocarcinoma and adenosquamous carcinoma within one pathway, driven by FIGO stage rather than by histological type. The exception the guidelines do carve out is neuroendocrine carcinoma, which is managed separately — which is precisely why a mixed tumour should be checked for a neuroendocrine component before the plan is fixed. Sources: NCCN Guidelines for Cervical Cancer; FIGO 2018 staging for carcinoma of the cervix uteri.
How Adenosquamous Cervical Cancer Is Treated
Because the pathway is stage-driven, the options will look familiar to anyone who has read about the pure types:
Early stage — surgery with lymph node assessment
Removal of the cervix and the surrounding tissue, with the pelvic nodes assessed. If the specimen shows involved margins, positive nodes or extensive lymphovascular invasion, treatment after surgery is usually recommended. Fertility-sparing surgery is considered case by case and requires a small tumour, clear staging and a frank discussion of the uncertainties.
Locally advanced — chemoradiation followed by brachytherapy
External radiation to the pelvis with platinum-based chemotherapy given alongside it, then brachytherapy, where the radiation source is placed against the tumour. NCCN, FIGO and ESMO all regard brachytherapy as an essential part of curative treatment at this stage, and completing it within the planned overall treatment time matters as much as the dose.
Advanced or recurrent — systemic treatment, guided by testing
Chemotherapy is the backbone, with targeted therapy and checkpoint immunotherapy considered according to what testing of the tumour shows, including PD-L1 status. Radiation may be added to control specific symptoms. The regimens are individual decisions, set out on our cervical cancer treatment in Hyderabad page.
If there is one message to take from an uncommon histology report, it is this: the rarity of the label is not the same as the severity of the disease. Get the diagnosis confirmed, get the staging completed, and let a team rather than a single opinion decide the plan.
Why Rare Cervical Histology Is Handled Carefully at CION
Uncommon does not have to mean uncertain. It means the diagnostic work is done properly before anything else begins.
Pathology confirmed before treatment
Tumour board for every diagnosis
Slide and block review arranged
MRI and PET-CT under one roof
Brachytherapy planned from day one
45-minute detailed consultation
7 NABH-accredited Hyderabad locations
EMI facility & insurance accepted
4.8 / 5 Google rating
Take The Next Step
Get the Label Settled, Then Get the Plan
A mixed diagnosis is worth an hour with someone who reads these reports every week. Bring the report and the scans, and ask everything.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Adenosquamous & Mixed Cervical Cancers — Frequently Asked Questions
What does adenosquamous carcinoma of the cervix mean?
It means one cervical tumour contains two malignant components — a glandular part, arising from the mucus-producing cells that line the cervical canal, and a squamous part, arising from the flat cells covering the outer cervix. It is not two separate cancers. The cervix has a border zone where both cell types meet, and a cancer starting there can differentiate in both directions. Adenosquamous carcinoma is uncommon and is usually associated with high-risk HPV. Importantly, it is staged with the same FIGO 2018 system and treated on the same stage-driven pathway as the pure squamous and glandular types.
Is adenosquamous cervical cancer more aggressive than the pure types?
The published evidence is genuinely mixed. Some series have reported less favourable outcomes for adenosquamous tumours; others find no meaningful difference once stage, tumour size and lymph node status are taken into account. Nobody can honestly tell you that the label alone determines your outlook. What is consistent across the evidence is that the stage at which the cancer is found, whether lymph nodes are involved, and whether the planned treatment — particularly brachytherapy, where it is part of the plan — is completed on schedule, matter far more. Those are the things your team can influence.
What is glassy cell carcinoma of the cervix?
Glassy cell carcinoma is a poorly differentiated form of adenosquamous carcinoma, named for the ground-glass appearance of the tumour cells under the microscope. In the current WHO classification it is not treated as a separate disease entity but as a variant within the adenosquamous group. It is uncommon, and it has historically been regarded as behaving aggressively, which is a reason to complete staging promptly and avoid gaps between steps rather than a reason to abandon the standard approach. Staging and treatment follow the usual cervical cancer framework, decided by FIGO stage.
Why did my biopsy say adenocarcinoma but my surgery report says adenosquamous?
This is common and it is usually a sampling issue rather than a change in the disease. A punch biopsy takes a few millimetres of tissue; a surgical specimen contains the whole tumour. If the glandular and squamous components are unevenly distributed, the small sample may have captured only one of them. The larger specimen simply gives the pathologist a fuller view. It does not mean the cancer transformed or progressed between the two procedures. What it does mean is that the surgical report is the more complete document, and it is the one your treatment plan should be built on.
Do I need different treatment because my cervical tumour is mixed?
In almost all cases, no. NCCN Guidelines handle squamous cell carcinoma, adenocarcinoma and adenosquamous carcinoma of the cervix within a single stage-driven algorithm — surgery with lymph node assessment for early disease, chemoradiation followed by brachytherapy for locally advanced disease, and systemic treatment for advanced or recurrent disease. The one finding that genuinely changes the pathway is a neuroendocrine component, which is managed separately and which is why a mixed tumour should be checked for it specifically. Beyond that, your stage, tumour size and node status decide the plan, not the histology label.
Medical disclaimer: This page is general health information, reviewed by a CION oncologist. It is not a diagnosis, a stage or a treatment recommendation, and it cannot replace review of your own pathology and imaging by a specialist. Please discuss your report with your treating team before making any decision about treatment.